Mihaela Stana
Research Subjects
Mihaela Stana has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Kristina Jankovic
Clinic of Oncology, University Clinical Centre Nis, 18000 Nis, Serbia
2 shared publications - Luca Arecco
Institut Jules Bordet, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles(H.U.B) , Bruxelles
2 shared publications - Luciana de Moura Leite
Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
2 shared publications - Matteo Lambertini
Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova , Genoa
2 shared publications - Abeid Omar
Department of Oncology and Nuclear Medicine, Research and Referral Hospital Kenyatta Teaching University, Nairobi, Kenya
1 shared publication Gabriella Gentile
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 7 June 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (8) , 1452-1466
Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies
In recent years, cancer treatment has been revolutionized by the introduction of many novel drugs, including immunotherapy and targeted agents, which have significantly improved the prognosis of patients with different solid tumors. While the role of traditional cytotoxic agents on fertility and reproductive health of patients with cancer is currently well established, the impact of novel treatments remains an unmet medical need and a subject of concern. Limited clinical evidence exists to date on the potential gonadotoxicity of targeted agents and immunotherapy. However, in preclinical male and female animal models, several new treatments have demonstrated the potential to affect reproductive capacity. Hence, the possible impact of these treatments on patients’ reproductive potential should be urgently addressed. This work aims to review the most recent evidence regarding the gonadotoxicity of immunotherapy and novel targeted agents from the mechanisms of action of these treatments to the preclinical and clinical available data, as well as the implications on chances and risks of subsequent pregnancies. The final aim is to provide a useful tool to both physicians and patients for an informed decision-making process regarding fertility preservation and family planning before and after exposure to the new anticancer treatments.
- 7 June 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (8) , 1452-1466
Top Cited PapersOpen AccessGonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies
In recent years, cancer treatment has been revolutionized by the introduction of many novel drugs, including immunotherapy and targeted agents, which have significantly improved the prognosis of patients with different solid tumors. While the role of traditional cytotoxic agents on fertility and reproductive health of patients with cancer is currently well established, the impact of novel treatments remains an unmet medical need and a subject of concern. Limited clinical evidence exists to date on the potential gonadotoxicity of targeted agents and immunotherapy. However, in preclinical male and female animal models, several new treatments have demonstrated the potential to affect reproductive capacity. Hence, the possible impact of these treatments on patients’ reproductive potential should be urgently addressed. This work aims to review the most recent evidence regarding the gonadotoxicity of immunotherapy and novel targeted agents from the mechanisms of action of these treatments to the preclinical and clinical available data, as well as the implications on chances and risks of subsequent pregnancies. The final aim is to provide a useful tool to both physicians and patients for an informed decision-making process regarding fertility preservation and family planning before and after exposure to the new anticancer treatments.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (4) , 578-579
The Value of Offering Oncofertility Counseling in Young Patients With Newly Diagnosed Cancer Is Unquestionable
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (4) , 578-579
The Value of Offering Oncofertility Counseling in Young Patients With Newly Diagnosed Cancer Is Unquestionable